The role of microRNAs in prethrombotic status associated with coronary artery disease

Summary

The acute cardiovascular events following thrombus formation is a primary cause of morbidity and mortality of patients with coronary artery disease (CAD). Numerous studies have shown that a prethrombotic status, which can be defined as an imbalance between the procoagulant and anticoagulant conditions, would exist for a period of time before thrombogenesis. Therefore, early diagnosis and intervention of prethrombotic status are important for reducing acute cardiovascular events. However, none of prethrombotic indicators have been identified as golden standard for diagnosis of prethrombotic status to date. MicroRNAs (miRNAs), a class of short non-coding RNAs, have been shown to be involved in pathophysiologic processes related to prethrombotic status, such as endothelial dysfunction, platelet activation, impaired fibrinolysis and elevated procoagulant factors, etc. Owing to their multiple and fine-tuning impacts on gene expression, miRNAs raise a novel understanding in the underlying mechanism of prethrombotic status. This review aims to discuss the role of miRNAs in prethrombotic status, especially the differently expressed miRNAs in CAD, which may be meaningful for developing promising diagnostic biomarkers and therapeutic strategies for CAD patients in future.

Keywords

MicroRNAs - prethrombotic status - coronary artery disease - biomarkers

• References

• 1 Ruff CT, Braunwald E.. The evolving epidemiology of acute coronary syndromes. Nat Rev Cardiol 2011; 08: 140-147.
• 2 Orbe J. et al. Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thromb Haemost 2008; 99: 382-387.
• 3 Smid M. et al. Thrombin generation in patients with a first acute myocardial infarction. J Thromb Haemost 2011; 09: 450-456.
• 4 Bauer KA, Rosenberg RD.. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-350.
• 5 López Y. et al. Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thromb Res 1999; 93: 71-78.
• 6 Musunuru K. et al. Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association. Circ Cardiovasc Genet 2015; 08: 216-242.
• 7 Small EM. et al. MicroRNAs add a new dimension to cardiovascular disease. Circulation 2010; 121: 1022-1032.
• 8 van Rooij E.. The art of microRNA research. Circ Res 2011; 108: 219-234.
• 9 Thum T, Condorelli G.. Long noncoding RNAs and microRNAs in cardiovascular pathophysiology. Circ Res 2015; 116: 751-762.
• 10 Furie B, Furie BC.. Mechanisms of thrombus formation. N Engl J Med 2008; 359: 938-949.
• 11 Gutiérrez E. et al. Endothelial dysfunction over the course of coronary artery disease. Eur Heart J 2015; 60: 3175-3181.
• 12 Ettenson DS, Gotlieb AI.. Endothelial repair. CMAJ 1990; 142: 601.
• 13 Toya SP, Malik AB.. Role of endothelial injury in disease mechanisms and contribution of progenitor cells in mediating endothelial repair. Immunobiology 2012; 217: 569-580.
• 14 Lin Z. et al. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res 2005; 96: e48-57.
• 15 Lin Z. et al. Kruppel-like factor 2 inhibits protease activated receptor-1 expression and thrombin-mediated endothelial activation. Arterioscler Thromb Vasc Biol 2006; 26: 1185-1189.
• 16 Hamik A. et al. Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem 2007; 282: 13769-13779.
• 17 Hartmann P. et al. Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4. Nat Commun 2016; 07: 10521.
• 18 Fang Y, Davies PF.. Site-specific microRNA-92a regulation of krüppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler Thromb Vasc Biol 2012; 32: 979-987.
• 19 Wu W. et al. Flow-dependent regulation of krüppel-like factor 2 is mediated by microRNA-92a. Circulation 2011; 124: 633-641.
• 20 Loyer X. et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res 2014; 114: 434-443.
• 21 Bonauer A. et al. MicroRNA-92a controls angiogenesis and functional recovery of ischaemic tissues in mice. Science 2009; 324: 1710-1713.
• 22 Guarani V. et al. Acetylation-dependent regulation of endothelial notch signalling by the SIRT1 deacetylase. Nature 2011; 473: 234-238.
• 23 Iaconetti C. et al. Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury. Basic Res Cardiol 2012; 107: 296.
• 24 Daniel JM. et al. Inhibition of miR-92a improves re-endothelialisation and prevents neointima formation following vascular injury. Cardiovasc Res 2014; 103: 564-572.
• 25 Chen C. et al. MiR-320a contributes to atherogenesis by augmenting multiple risk factors and down-regulating SRF. J Cell Mol Med 2015; 19: 970-985.
• 26 Weber M. et al. MiRNA-155 targets myosin light chain kinase and modulates actin cytoskeleton organisation in endothelial cells. Am J Physiol Heart Circ Physiol 2014; 306: 1192-1203.
• 27 Qin X. et al. MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. Proc Natl Acad Sci USA 2010; 107: 3240-3244.
• 28 Shi L. et al. MicroRNA-223 antagonizes angiogenesis by targeting ß1 integrin and preventing growth factor signalling in endothelial cells. Circ Res 2013; 113: 1320-1330.
• 29 Wang KC. et al. Role of microRNA-23b in flow-regulation of Rb phosphorylation and endothelial cell growth. Proc Natl Acad Sci USA 2010; 107: 3234-3239.
• 30 Chen K. et al. MicroRNA-101 mediates the suppressive effect of laminar shear stress on mTOR expression in vascular endothelial cells. Biochem Biophys Res Commun 2012; 427: 138-142.
• 31 Lu C. et al. Attenuation of cardiac dysfunction and remodeling of myocardial infarction by microRNA-130a are mediated by suppression of PTEN and activation of PI3K dependent signalling. J Mol Cell Cardiol 2015; 89: 87-97.
• 32 Rajput C. et al. MicroRNA-150 suppression of angiopoetin-2 generation and signalling is crucial for resolving vascular injury. Arterioscler Thromb Vasc Biol 2016; 36: 380-388.
• 33 Agouni A. et al. Microparticles as biomarkers of vascular dysfunction in metabolic syndrome and its individual components. Curr Vasc Pharmacol 2014; 12: 483-492.
• 34 Diehl P. et al. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res 2012; 93: 633-644.
• 35 Zernecke A. et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 02: ra81.
• 36 Jansen F. et al. Endothelial microparticle-mediated transfer of microRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 2013; 128: 2026-2038.
• 37 Wang S. et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15: 261-271.
• 38 Fish JE. et al. MiR-126 regulates angiogenic signalling and vascular integrity. Dev Cell 2008; 15: 272-284.
• 39 Schober A. et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 2014; 20: 368-376.
• 40 Pan Y. et al. Platelet-secreted microRNA-223 promotes endothelial cell apoptosis induced by advanced glycation end products via targeting the insulin-like growth factor 1 receptor. J Immunol 2014; 192: 437-446.
• 41 Hill JM. et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
• 42 Kane NM. et al. Role of microRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells. Stem Cells 2012; 30: 643-654.
• 43 Tano N. et al. MicroRNA-150 regulates mobilisation and migration of bone marrow-derived mononuclear cells by targeting cxcr4. PLoS One 2011; 06: e23114.
• 44 Meng Q. et al. Upregulation of microRNA-126 contributes to endothelial progenitor cell function in deep vein thrombosis via its target PIK3R2. J Cell Biochem 2015; 116: 1613-1623.
• 45 Wang HW. et al. Deficiency of the microRNA-31-microRNA-720 pathway in the plasma and endothelial progenitor cells from patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2014; 34: 857-869.
• 46 Meng S. et al. MicroRNA 107 partly inhibits endothelial progenitor cells differentiation via HIF-1ß. PLoS One 2012; 07: e40323.
• 47 Wang S. et al. MiR-23a regulates the vasculogenesis of coronary artery disease by targeting epidermal growth factor receptor. Cardiovasc Ther 2016; 34: 199-208.
• 48 Tang Y. et al. Role of the microRNA, miR-206, and its target PIK3C2a in endothelial progenitor cell function - potential link with coronary artery disease. FEBS J 2015; 282: 3758-3772.
• 49 Zuo K. et al. A dysregulated microRNA-26a/EphA2 axis impairs endothelial progenitor cell function via the p38 MAPK/VEGF pathway. Cell Physiol Biochem 2015; 35: 477-488.
• 50 Nagalla S. et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 2011; 117: 5189-5197.
• 51 Plé H. et al. The repertoire and features of human platelet microRNAs. PLoS One 2012; 07: e50746.
• 52 Edelstein LC, Bray PF.. MicroRNAs in platelet production and activation. Blood 2011; 117: 5289-5296.
• 53 Kahraman T. et al. Abstract 1934 Platelet activation regulates levels of microRNA. Circulation 2008; 118: S407.
• 54 Cimmino G. et al. Platelet activation results in modulation of microRNA expression profile: new insights into the pathophysiology of platelet activation. Circulation 2012; 126: A12998.
• 55 Boos CJ. et al. Circulating endothelial cells and von Willebrand factor as indices of endothelial damage/dysfunction in coronary artery disease: a comparison of central vs. peripheral levels and effects of coronary angioplasty. J Thromb Haemost 2007; 05: 630-632.
• 56 de Boer HC. et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J 2013; 34: 3451-3457.
• 57 Cavarretta E. et al. Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra. Eur Heart J 2013; 34: 3400-3402.
• 58 Kondkar AA. et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010; 08: 369-378.
• 59 Chen S. et al. Expression of miRNA-26a in platelets is associated with clopidogrel resistance following coronary stenting. Exp Ther Med 2016; 12: 518-524.
• 60 Landry P. et al. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009; 16: 961-966.
• 61 Kaudewitz D. et al. Association of microRNAs and YRNAs with platelet function. Circ Res 2016; 118: 420-432.
• 62 Sondermeijer BM. et al. Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340* and miRNA624*. PLoS One 2011; 06: e25946.
• 63 Chen F. et al. Integrated microRNA-mRNA analysis of coronary artery disease. Mol Biol Rep 2014; 41: 5505-5511.
• 64 Li SF. et al. Circulating microRNAs as potential biomarkers of coagulation dysfunction in patients with vulnerable voronary artery disease. Heart 2013; 99: A103-A104.
• 65 Salloum-Asfar S. et al. Regulation of coagulation factor XI expression by microRNAs in the human liver. PLoS One 2014; 09: e111713.
• 66 Li S. et al. MicroRNA-19b functions as potential anti-thrombotic protector in patients with unstable angina by targeting tissue factor. J Mol Cell Cardiol 2014; 75: 49-57.
• 67 Li S. et al. MicroRNA-223 inhibits tissue factor expression in vascular endothelial cells. Atherosclerosis 2014; 237: 514-520.
• 68 Witkowski M. et al. Micro-RNA-126 Reduces the Blood Thrombogenicity in Diabetes Mellitus via Targeting of Tissue Factor. Arterioscler Thromb Vasc Biol 2016; 36: 1263-1271.
• 69 Teruel R. et al. Potential role of miRNAs in developmental haemostasis. PLoS One 2011; 06: e17648.
• 70 Fort A. et al. Regulation of fibrinogen production by microRNAs. Blood 2010; 116: 2608-2615.
• 71 Patel N. et al. Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells. Biochem J 2011; 434: 473-482.
• 72 Zampetaki A. et al. Abstract 17100 MicroRNAs and Risk of Myocardial Infarction: Prospective Results from the Bruneck Study. Circulation 2012; 126: A17100.
• 73 Marchand A. et al. MiR-421 and miR-30c inhibit SERPINE 1 gene expression in human endothelial cells. PLoS One 2012; 07: e44532.
• 74 Chen YS. et al. Levels of microRNA-181b and plasminogen activator inhibitor-1 are associated with hypertensive disorders complicating pregnancy. Exp Ther Med 2014; 08: 1523-1527.
• 75 Ariëns RA. et al. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 2002; 359: 667-671.
• 76 Wei Y. et al. MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis?. Arterioscler Thromb Vasc Biol 2013; 33: 449-454.
• 77 Schulte C. et al. MiRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease. PLoS One 2015; 10: e0145930.
• 78 Karakas M. et al. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large AtheroGene study. Eur Heart J 2016. pii ehw250.
• 79 Chen X. et al. Characterisation of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
• 80 Wang J. et al. Altered serum microRNAs as novel diagnostic biomarkers for atypical coronary artery disease. PLoS One 2014; 09: e107012.
• 81 Fichtlscherer S. et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 107: 677-684.
• 82 Han H. et al. MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32 patient cohort. Exp Mol Med 2015; 47: e138.
• 83 Zampetaki A. et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107: 810-817.
• 84 Ortega FJ. et al. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitzation. Diabetes Care 2014; 37: 1375-1383.
• 85 Olivieri F. et al. MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications. Oncotarget 2015; 06: 35372-35382.
• 86 Zampetaki A. et al. Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012; 60: 290-299.
• 87 Navickas R. et al. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res 2016; 111: 322-337.
• 88 Jansen F. et al. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc 2014; 03: e001249.
• 89 Weber M. et al. MicroRNA expression profile in CAD patients and the impact of ACEI/ARB. Cardiol Res Pract 2011; 2011: 1-5.
• 90 Li J. et al. Effects of statin on circulating microRNAome and predicted function regulatory network in patients with unstable angina. BMC Med Genomics 2015; 08: 12.
• 91 Santovito D. et al. Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control. J Clin Endocrinol Metab 2014; 99: E1681-1685.
• 92 Willeit P. et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013; 112: 595-600.
• 93 Zhang YY. et al. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. J Thromb Thrombolysis 2014; 38: 65-72.
• 94 Carino A. et al. Modulation of circulating microRNAs levels during the switch from clopidogrel to ticagrelor. Biomed Res Int 2016; 2016: 1-5.
• 95 Wronska A. et al. Application of microRNAs in diagnosis and treatment of cardiovascular disease. Acta Physiol 2015; 213: 60-83.
• 96 Santulli G. et al. A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. J Clin Invest 2014; 124: 4102-4114.
• 97 McDonald RA. et al. Reducing in-stent restenosis: therapeutic manipulation of miRNA in vascular remodeling and inflammation. J Am Coll Cardiol 2015; 65: 2314-2327.
• 98 Wang D. et al. Local microRNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis. Arterioscler Thromb Vasc Biol 2015; 35: 1945-1953.
• 99 Edelstein LC. et al. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med 2013; 19: 1609-1616.
• 100 Büning H.. Gene therapy enters the pharma market: The short story of a long journey. EMBO Mol Med 2013; 05: 1-3.
• 101 Bouchie A.. First microRnA mimic enters clinic. Nat Biotechnol 2013; 31: 577.
• 102 Janssen HL. et al. Treatment of HCV Infection by Targeting MicroRNA. N Engl J Med 2013; 368: 1685-1694.